Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia
Danielle M Brander, Andrew W Roberts, Thomas J Kipps, Shuo Ma, Mary Ann Anderson, Michelle Boyer, Piers Blombery, Relja Popovic, Jordan Roser, Zhuangzhuang Liu, Brenda Chyla, John F Seymour · 2025
Read Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia by Danielle M Brander, Andrew W Roberts, Thomas J Kipps, Shuo Ma, Mary Ann Anderson, Michelle Boyer, Piers Blombery, Relja Popovic, Jordan Roser, Zhuangzhuang Liu, Brenda Chyla, John F Seymour (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12745032.txt.
Description
Danielle Brander and co-authors study whether a drug pair can work a second time in chronic lymphocytic leukemia. The pair joins venetoclax, which blocks a protein that helps cancer cells survive, with an antibody drug. Given for a fixed span of up to two years, the pair can bring deep remissions that last off treatment.
Most patients still relapse in time, and choices after relapse are limited. The question is whether repeating a past winning pair extends control without breeding resistance. Fixed length courses also cut cost and side effects versus nonstop therapy. The analysis draws on a trial where patients in deep response could stop and later restart. Results inform how doctors sequence care.
Catalog record
| CREATOR | Danielle M Brander, Andrew W Roberts, Thomas J Kipps, Shuo Ma, Mary Ann Anderson, Michelle Boyer, Piers Blombery, Relja Popovic, Jordan Roser, Zhuangzhuang Liu, Brenda Chyla, John F Seymour |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |